Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have described heterocyclic derivatives acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Ono Pharmaceutical Co. Ltd. has entered into a worldwide drug discovery collaboration agreement with Macomics Ltd. to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer.
Kita-Kyushu lung cancer antigen-1 (KK-LC-1) is a member of the cancer/testis antigens (CTAs) protein family, which is family of proteins that are mainly expressed in tumors and testicular tissue, but they display low to no expression in other normal tissues.
Oxford Drug Design Ltd. has been engaged by Phoremost Ltd. to accelerate a targeted protein degradation discovery program that seeks to identify new E3 ligase-based therapeutic strategies to treat cancer.
Shuttle Pharmaceuticals Holdings Inc. has entered a research agreement with Georgetown University focused on the evaluation of the company's lead histone deacetylase 6 (HDAC6) inhibitor candidate, SP-2-225, evaluating the antitumor effect of the combination of SP-2-225 and radiation therapy in a syngeneic breast cancer model.
A research group at Washington University School of Medicine has released animal data showing restriction of tumor growth with a novel mRNA therapeutic delivered in nanoparticles based on Altamira Therapeutics Ltd.’s Semaphore delivery platform.
While Moderna Inc. CEO Stéphane Bancel was the one on the hot seat at a March 22 hearing before the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee, biopharma profitability in general, and capitalism itself, came under fire as committee Chair Bernie Sanders (I-Vt.) railed about corporate greed in the sector.
Flare Therapeutics Inc. raised $123 million in an oversubscribed series B round to take its lead compound, FX-909, a potentially first-in-class peroxisome proliferator-activated receptor gamma inhibitor, into clinical trials in patients with advanced urothelial cancer and to advance additional pipeline candidates acting on other transcription factor targets with genetically validated links to disease biology.
Astellas Pharma Inc.’s zolbetuximab, a monoclonal antibody targeting Claudin 18.2, met the primary endpoint for progression-free survival as well as secondary endpoints for overall survival in the phase III Glow trial in CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
RSS
